UBS Maintains Neutral on Aflac, Raises Price Target to $125
UBS analyst Michael Ward maintains Aflac (NYSE:AFL) with a Neutral and raises the price target from $124 to $125.
Stocks · News reference
Cramer backs Sphere and Cameco, urges selling AppLovin, criticizes Honeywell and QXO, and sees limited-risk upside in Aflac.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Michael Ward maintains Aflac (NYSE:AFL) with a Neutral and raises the price target from $124 to $125.
MetLife's Group Benefits segment reported 25% year-over-year earnings growth in Q2 2026, driven by volume growth and improved underwriting. Group Life's mortality ratio improved to 79%, below the 83%-88% target range. However, some mortality benefits may not persist as about 2 percentage points reflected prior-period development. Competitors The Hartford and Aflac showed mixed results, with Hartford's employee benefits expanding but facing higher disability loss ratios, while Aflac's earnings declined despite sales growth.
Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:APP) with a Buy and maintains $475 price target.
The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.
Unity Software shares are rising Monday. Piper Sandler reiterated its rating and price target ahead of the company's third-quarter report.
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.